Lijing Su

Lijing Su has a diverse work experience in the field of structural biology and drug discovery.

They started their career as a Research Assistant at the University of Science and Technology of China, where they managed various cell types and published a first-author paper.

After that, they worked as a Research Assistant at Oklahoma State University, where they gained expertise in molecular biology and physiology and co-authored six papers.

Lijing then pursued their Ph.D. in Biophysics at the University of Texas Southwestern Medical Center. During their doctoral studies, they conducted structural characterization of candidate vaccine adjuvants and anti-tumor drugs, validated protein-protein interactions, and participated in international collaborations for innate immune agonist discovery.

Following their Ph.D., Lijing continued their research at the same institution as a Postdoctoral Researcher and later as an Assistant Professor at the Center for the Genetics of Host Defense. In these roles, they led structural biology efforts, characterized multiprotein complexes related to immunity, and participated in drug optimization projects.

In 2021, Lijing joined Kymera Therapeutics as a Senior Scientist, where they led structure biology efforts, oversaw lead optimization, and established cryoEM capabilities. Subsequently, they transitioned to the role of Principal Scientist.

Currently, Lijing Su works at Entact Bio as the Principal Scientist and Head of Structural Sciences.

Lijing Su pursued their Bachelor's degree in Bioscience from the University of Science and Technology of China between 2002 and 2006. Following that, from 2009 to 2013, they attended UT Southwestern Medical Center to study biochemistry and biophysics.